Search

Author/Creator Bejou, Nika

1. 1015. Gastrointestinal (GI) Adverse Events With Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Through Week 96: An AMBER Post Hoc Analysis. (31st December 2020)

Authors:
Dunn, Keith; Huang, Yangxin; Baugh, Bryan; Bejou, Nika; Luo, Donghan; Campbell, Jennifer; Anderson, David
Journal:
Open forum infectious diseases
Issue:
Volume 7:Number 1(2020) Supplement
Page Start:
S536
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1797. Combining Rapid Diagnostics With Pharmacy Resident-Led Antimicrobial Stewardship to Optimize Outcomes for Bacteremia With Methicillin-Resistant S. aureus (MRSA-B), Methicillin-Susceptible S. aureus (MSSA-B), and Coagulase-Negative Staphylococcus (CoNS) at Yale New Haven Hospital (YNHH). (26th November 2018)

Authors:
Bejou, Nika; McManus, Dayna; Peaper, David; Topal, Jeffrey
Journal:
Open forum infectious diseases
Issue:
Volume 5(2018)Supplement 1
Page Start:
S509
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD. (April 2022)

Authors:
Dunn, Keith; Baugh, Bryan; Bejou, Nika; Luo, Donghan; Campbell, Jennifer; Seyedkazemi, Sareh; Anderson, David
Journal:
Journal of the International Association of Providers of AIDS Care
Issue:
Volume 21(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗